Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)

Rapid Diagnostic Test for COVID-19 Based on Antibody Detection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04490837

Acronym

YCOVID

Enrollment

3500

Registered

2020-07-29

Start date

2020-06-22

Completion date

2020-09-30

Last updated

2021-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Keywords

Antibodies, Covid-19, Rapid test, RBD

Brief summary

Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices. This test will be developed using innovative technology developed at the Parc Taulí University Hospital, which increases the immunogenicity of SARS-CoV-2 differential antigens. The increased immunogenicity of these antigens will allow to detect, with a high sensitivity and specificity, the antibodies in the serum of patients infected with SARS-CoV-2. This test will serve to confirm dubious results as well as reduce false negatives from the PCR test, which will ultimately help reduce transmission of the infection.

Interventions

DIAGNOSTIC_TESTELISA and Rapid test to detect antibodies against COVID-19

Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Professional from Parc Taulí University Hospital * Patients with clinical, radiological and/or PCR COVID-19 positive

Exclusion criteria

* Patients or professionals who do not sign informed consent

Design outcomes

Primary

Measure	Time frame	Description
IgG anti-COVID-19	From May to July	IgG antibodies against COVID-19 RBD
IgM anti-COVID-19	From May to July	IgM antibodies against COVID-19 RBD
IgA anti-COVID-19	From May to July	IgA antibodies against COVID-19 RBD

Secondary

Measure	Time frame	Description
Time of onset symptoms	From May to July	—
COVID-19 PCR results	From May to July	Qualitative result to clasify patients into PCR COVID-19 positive patients and PCR COVID-19 negative patients
Radiological studies	From May to July	The presence or abcense of the typical image of the pneumonia caused by COVID-19

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026